Purchase this article with an account.
Rod D. Braun, Kerry S. Vistisen; Modeling Human Choroidal Melanoma Xenograft Growth in Immunocompromised Rodents to Assess Treatment Efficacy. Invest. Ophthalmol. Vis. Sci. 2012;53(6):2693-2701. doi: https://doi.org/10.1167/iovs.11-9265.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate potential treatments of primary uveal melanoma in rodent xenograft models, it is necessary to track individual tumor growth during treatment. Previously, high-frequency ultrasound (HF-US) was usedto measure tumor volume in nude rats for up to 2 weeks. This study tests the hypothesis that HF-US can be used to repeatedly measure tumor volume for at least a month in both nude rat and severe combined immunodeficiency (SCID) mouse xenograft models of human uveal melanoma, with the goal of modeling tumor growth to evaluate treatment efficacy.
C918 human uveal melanoma spheroids were implanted in the choroids of six nude rats and six severe combined immunodeficiency mice. OCM-1 human uveal melanoma spheroids were implanted in six nude rats. Every 4–7 days thereafter for up to 5 weeks, HF-US images of the tumor-bearing eye were captured every 100 or 250 μm. Tumor areas were measured on each image and integrated to calculate volume. Tumor growth was modeled using a logistic curve, and parameters characterizing growth, including the time to reach a target volume (tT), were evaluated as potential measures of treatment efficacy.
Tumor volume could be measured for up to 5 weeks in all models, and the logistic curve described the growth well. The parameter tT was shown to be a suitable endpoint to evaluate treatments.
HF-US is a practical method to track uveal melanoma growth in the same nude rat or SCID mouse for up to a month. Such growth data can be used to evaluate treatments in these xenograft models.
This PDF is available to Subscribers Only